Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON Study: I-VRD Induction With or Without I-VRD Consolidation After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
KCT0009297Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Started Jul 2024; status: recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0009297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009297.